TY - JOUR AU - Lindarto, Dharma PY - 2014/05/31 Y2 - 2024/03/28 TI - Effect of Lifestyle Modification and Metformin on Fetuin-A in Metabolic Syndrome JF - Journal of the ASEAN Federation of Endocrine Societies JA - J ASEAN Fed Endocr Soc VL - 29 IS - 1 SE - Original Articles DO - UR - https://www.asean-endocrinejournal.org/index.php/JAFES/article/view/115 SP - 48 AB - <p>Objective. To evaluate the effects of lifestyle modification and metformin on fetuin-A in metabolic syndrome (MetS) as defined in 2006 by the International Diabetes Federation (IDF).</p><p class="Body"> </p><p>Methodology. Forty MetS subjects were randomly assigned to treatment with placebo (n=20) or metformin (n=20) in addition to lifestyle modification for 12 weeks.</p><p class="Body"> </p><p class="Body">Results. All 40 participants completed the study. After 12 weeks, both groups had significant reductions in weight (p&lt;0.001), body mass index (BMI) (p&lt;0.001), waist circumference (WC) (p&lt;0.001), systolic blood pressure (SBP) (p&lt;0.001), and diastolic blood pressure (DBP) (p&lt;0.001). The placebo group also had significant improvement in fasting plasma glucose (FPG) (p&lt;0.001) and C-reactive protein (CRP) (&lt;0.05). Weight, BMI, WC, FPG, 2-hour postprandial glucose (2h-PPG), high density lipoprotein cholesterol (HDL-C), triglycerides (TG) and fetuin-A in the metformin group decreased significantly compared to the placebo group. Reduction of plasma fetuin-A was significantly associated with TG in the metformin group.</p><p class="Body"> </p>Conclusion. Lifestyle modification and treatment with metformin for 12 weeks improved cardio-metabolic risk factors in MetS and reduced fetuin-A levels. Further investigations are required to confirm the effects of lifestyle modification and metformin after an extended follow-up period. ER -